InvestorsHub Logo

Pasta

12/11/14 7:57 AM

#35182 RE: jdjlaw #35181

By upgrading to the nasdaq they bring in more money to pay themselves.

RandyK

12/11/14 9:06 AM

#35186 RE: jdjlaw #35181

Amen LawMan we see this the same way.

mcsharkey

12/11/14 7:45 PM

#35204 RE: jdjlaw #35181

Yeah JD, on Joe our new board member, still rumbling back and forth with it. I do hope he pulls his weight, and our assets out of this damn hole. Dunno if the board member page on the ADNAS website is up to date (well, it doesn't have Joe on it, but these are the members it does list (I thought there were a few more).

Dunno. These guys been familiar with each other for a while. So how far afield they actually go, I still dunno. Here's the group of Villains, Thieves and Scoundrels themselves:).

I actually am in general favor of our Dr Hayward (all these guys are PHDs) and the board. Just wondering WHY NOW. Like $10Mill![/quote]Applied DNA Sciences Board of Directors
James A. Hayward - Chairman of the Board, President and Chief Executive Officer since June 12, 2007. Also chaired the Collaborative Group where he ran with Joe from 1990 through 2004
Yacov Shamash - Director

Dr. Yacov Shamash since March 17, 2006. Founder of the New York State Center for Excellence in Wireless Technologies (CEWIT) and The Advanced Energy Research & Technology Center (AERTC).

Sanford R. Simon - March 17, 2006. Dr. Simon has been a Professor of Biochemistry, Cell Biology and Pathology at Stony Brook Dr. Simon was a member of the Board of Directors of The Collaborative Group from 1995 to 2004. From 1967 to 1969 Dr. Simon was a Guest Investigator at Rockefeller University.

Ming-Hwa Benjamin Liang - Corporate Secretary and Strategic Technology Development Officer since October 2005.

Charles Ryan joined the Board of Directors on August 10, 2011. Also Sr. Vice President, and Chief Intellectual Property Counsel at Forest Laboratories, where he has been employed since 2003. Forest, with a market capitalization of nearly $10 billion, develops and markets pharmaceutical products in a variety of therapeutic categories including central nervous system, cardiovascular, anti-infective, respiratory, gastrointestinal, and pain management medicine.

John Bitzer, III joined the Board of Directors on August 10, 2011.